SOURCE Maxwell Biotech Venture Fund
MOSCOW, April 4, 2017 /PRNewswire/ --
Hepatera
LLC and its development partner MYR GmbH today announced the completion of recruitment for MYR 202 and 203 clinical trials, a Phase 2b program investigating Myrcudex B in chronic hepatitis delta infection. 180 subjects have been enrolled in 20 centers in Russia and Germany.
(Logo: http://photos.prnewswire.